Annual report pursuant to Section 13 and 15(d)

Supplemental Equity and Accumulated Other Comprehensive Income (loss) Information - Narrative (Details)

v3.22.2.2
Supplemental Equity and Accumulated Other Comprehensive Income (loss) Information - Narrative (Details) - USD ($)
$ / shares in Units, $ in Thousands
 12 Months Ended
Jun. 30, 2022
Jun. 30, 2021
Jun. 30, 2020
Common Stock, Dividends, Per Share, Declared (in dollars per share) $ 1.28 $ 1.28 $ 1.28
Stock Repurchased During Period, Shares (in shares) 394,238 120,000 279,381
Average price per share of shares repurchased $ 408.26 $ 359.81 $ 179.37
Interest Expense, Total $ 11,309 $ 13,952 $ 19,197
Total other income (expense), net 4,796 (89,121) 119,058
Income Tax Expense (Benefit), Total 38,287 8,590 47,181
Net Deferred Tax Liability 175,217 180,008  
Deferred Income Tax Expense (Benefit), Total 7,063 (28,013) 13,607
Changzhou Eminence Biotechnology [Member]      
Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Portion Attributable to Noncontrolling Interest 70 103  
AOCI Attributable to Parent [Member]      
Deferred Income Tax Expense (Benefit), Total 2,480 (1,908) (4,058)
Reclassification out of Accumulated Other Comprehensive Income [Member] | AOCI Attributable to Parent [Member]      
Interest Expense, Total 6,352 8,598 4,503
Total other income (expense), net   512  
Reclassification from AOCI, Current Period, Tax, Total $ 1,493 $ 2,150 $ 1,040